ANR 94 - CAS 634924-89-3
Catalog number: 634924-89-3
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C9H13N5O
Molecular Weight:
207.23
COA:
Inquire
Targets:
Adenosine A2a
Description:
Adenosine A2A antagonist
Publictions citing BOC Sciences Products
  • >> More
Brife Description:
Adenosine A2A antagonist
Appearance:
Off-White Solid
Synonyms:
8-Ethoxy-9-ethyl-9H-purin-6-amine
Solubility:
Soluble to 50 mM in DMSO and to 100 mM in ethanol
Storage:
Store at RT
MSDS:
Inquire
Quality Standard:
In-house
Quantity:
Grams-Kilos
Boiling Point:
~394.4° C at 760 mmHg (Predicted)
Melting Point:
168.77° C (Predicted)
InChIKey:
QUGDTMONBLMLLD-UHFFFAOYSA-N
InChI:
1S/C9H13N5O/c1-3-14-8-6(7(10)11-5-12-8)13-9(14)15-4-2/h5H,3-4H2,1-2H3,(H2,10,11,12)
Canonical SMILES:
CCN1C2=C(C(=NC=N2)N)N=C1OCC
1.New adenosine A2A receptor antagonists: actions on Parkinson's disease models.
Pinna A1, Volpini R, Cristalli G, Morelli M. Eur J Pharmacol. 2005 Apr 11;512(2-3):157-64.
The 8-substituted 9-ethyladenine derivatives: 8-bromo-9-ethyladenine (ANR 82), 8-ethoxy- 9-ethyladenine (ANR 94), and 8-furyl-9-ethyladenine (ANR 152) have been characterized in vitro as adenosine receptor antagonists. Adenosine is deeply involved in the control of motor behaviour and substantial evidences indicate that adenosine A(2A) receptor antagonists improve motor deficits in animal models of Parkinson's disease. On this basis, the efficacy of ANR 82, ANR 94, and ANR 152 in rat models of Parkinson's disease was evaluated. All compounds tested reversed the catalepsy induced by haloperidol. However, in unilaterally 6-hydroxydopamine-lesioned rats, only ANR 94 and ANR 152 potentiated l-dihydroxy-phenylalanine (l-DOPA) effect on turning behaviour and induced contralateral turning behaviour in rats sensitised to l-DOPA. Taken together the results of this study indicate that some 8-substituted 9-ethyladenine derivatives ameliorate motor deficits in rat models of Parkinson's disease, suggesting a potential therapeutic role of these compounds.
2.Dual target strategy: combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates L-DOPA-induced rotational behavior in a rodent model of Parkinson's disease.
Fuzzati-Armentero MT1, Cerri S1, Levandis G1, Ambrosi G1, Montepeloso E1, Antoninetti G1, Blandini F1, Baqi Y2,3, Müller CE2, Volpini R4, Costa G5, Simola N5, Pinna A6. J Neurochem. 2015 Aug;134(4):740-7. doi: 10.1111/jnc.13162. Epub 2015 Jun 4.
The glutamate metabotropic receptor 5 (mGluR5) and the adenosine A2A receptor (A2A R) represent major non-dopaminergic therapeutic targets in Parkinson's disease (PD) to improve motor symptoms and slow down/revert disease progression. The 6-hydroxydopamine rat model of PD was used to determine/compare the neuroprotective and behavioral impacts of single and combined administration of one mGluR5 antagonist, 2-methyl-6-(phenylethynyl)pyridine (MPEP), and two A2A R antagonists, (E)-phosphoric acid mono-[3-[8-[2-(3-methoxyphenyl)vinyl]-7-methyl-2,6-dioxo-1-prop-2-ynyl-1,2,6,7-tetrahydropurin-3-yl]propyl] (MSX-3) and 8-ethoxy-9-ethyladenine (ANR 94). Chronic treatment with MPEP or MSX-3 alone, but not with ANR 94, reduced the toxin-induced loss of dopaminergic neurons in the substantia nigra pars compacta. Combining MSX-3 and MPEP further improved the neuroprotective effect of either antagonists. At the behavioral level, ANR 94 and MSX-3 given alone significantly potentiated L-DOPA-induced turning behavior.
3.A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
Pinna A1, Tronci E, Schintu N, Simola N, Volpini R, Pontis S, Cristalli G, Morelli M. Neuropharmacology. 2010 Mar;58(3):613-23. doi: 10.1016/j.neuropharm.2009.11.012. Epub 2009 Dec 4.
Adenosine A(2A) receptor antagonists have emerged as an attractive non-dopaminergic target in clinical trials aimed at evaluating improvement in motor deficits in Parkinson's disease (PD). Moreover, preclinical studies suggest that A(2A) receptor antagonists may slow the course of the underlying neurodegeneration of dopaminergic neurons. In this study, we evaluated the efficacy of the new adenosine A(2A) receptor antagonist 8-ethoxy-9-ethyladenine (ANR 94) in parkinsonian models of akinesia and tremor. In addition, induction of the immediate early gene zif-268, and neuroprotective and anti-inflammatory effects of ANR 94 were evaluated. ANR 94 was effective in reversing parkinsonian tremor induced by the administration of tacrine. ANR 94 also counteracted akinesia (stepping test) and sensorimotor deficits (vibrissae-elicited forelimb-placing test), as well as potentiating l-dopa-induced contralateral turning behavior in 6-hydroxydopamine (6-OHDA) lesion model of PD.
4.In vitro metabolism studies of new adenosine A 2A receptor antagonists.
Marucci G1, Finaurini S, Buccioni M, Lammi C, Kandhavelu M, Volpini R, Ricciutelli M, Angeli P, Commandeur JN, Cristalli G. Drug Metab Lett. 2008 Dec;2(4):301-7.
Evidence, obtained in rodent and primate models of Parkinson's disease (PD) and in preliminary clinical trials, indicates that adenosine A(2A) receptor antagonists might represent a promising non-dopaminergic therapeutic tool for the treatment of PD. Recently, we have reported the biological evaluation of 8-substituted 9-ethyladenines (ANR) as new A(2A) receptor antagonists, three of which (ANR 82, ANR 94, and ANR 152) showed high efficacy in in vivo models for Parkinson's. Understanding the metabolic pathways of new drug candidates is an important aspect of drug discovery. The ANR compounds have been investigated in order to clarify their activity on rat liver microsomes, and more specifically on recombinant human cytochrome P450 2D6 (CYP2D6). The metabolites of all three compounds were detected by liquid chromatography/tandem mass spectrometry (LC-MS/MS). The results indicate that this class of 9-ethyladenines is metabolized only to a fraction of 1.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Adenosine A2a Products


SCH 58261
(CAS: 160098-96-4)

Potent, highly irreversible selective A2A antagonist

CAS 442908-10-3 Vipadenant

Vipadenant
(CAS: 442908-10-3)

Adenosine A2 receptor antagonists; Immunosuppressants

CAS 316173-57-6 SCH 442416

SCH 442416
(CAS: 316173-57-6)

Very selective, high affinity A2A antagonist

CAS 147700-11-6 8-(3-Chlorostyryl)caffeine

8-(3-Chlorostyryl)caffeine
(CAS: 147700-11-6)

Selective A2A antagonist. Also MAO-B inhibitor

CAS 155270-99-8 Istradefylline

Istradefylline
(CAS: 155270-99-8)

A very potent, selective and orally active adenosine A2A receptor antagonist(Ki=2.2 nM)

CAS 139180-30-6 ZM 241385

ZM 241385
(CAS: 139180-30-6)

Potent, highly selective A2A antagonist

CAS 913842-25-8 Lu AA 47070

Lu AA 47070
(CAS: 913842-25-8)

Prodrug of a potent and selective adenosine A2A receptor antagonist

CAS 870070-55-6 Tozadenant

Tozadenant
(CAS: 870070-55-6)

An orally administered, potent and selective inhibitor of the adenosine 2a (A2a) receptor

CAS 1061747-72-5 TC-G 1004

TC-G 1004
(CAS: 1061747-72-5)

Potent and selective A2A antagonist

CAS 54447-84-6 c-di-AMP

c-di-AMP
(CAS: 54447-84-6)

A2A inverse agonist; Also endogenous STING and DDX41 agonist

CAS 634924-89-3 ANR 94

ANR 94
(CAS: 634924-89-3)

Adenosine A2A antagonist

Chemical Structure

CAS 634924-89-3 ANR 94

Quick Inquiry

Verification code

Featured Items